Beef­ing up its CAR-T pipeline, Gilead teams up with Pfiz­er on a lym­phoma com­bo

Pfiz­er $PFE and Gilead $GILD are join­ing hands on a new com­bo pro­gram that will tie the CAR-T star Yescar­ta with an ear­ly-stage drug that has been bounc­ing around the clin­ic for the last few years.

Pfiz­er’s utomilum­ab (PF-05082566) is al­so in com­bo stud­ies with Keytru­da and Ky­owa Hakko Kirin’s an­ti-CCR4 an­ti­body moga­mulizum­ab. It’s a 4-1BB ag­o­nist, which re­searchers be­lieve could prove a key play­er in spurring an amped up T cell at­tack on can­cer cells among pa­tients with large B-cell lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER